StocksFundsScreenerSectorsWatchlists
CNTX

CNTX - Context Therapeutics Inc. Stock Price, Fair Value and News

1.30USD+0.03 (+2.36%)Market Closed

Market Summary

CNTX
USD1.30+0.03
Market Closed
2.36%

CNTX Stock Price

View Fullscreen

CNTX RSI Chart

CNTX Valuation

Market Cap

20.8M

Price/Earnings (Trailing)

-0.87

Price/Free Cashflow

-0.99

CNTX Price/Earnings (Trailing)

CNTX Profitability

Return on Equity

-201.87%

Return on Assets

-149.19%

Free Cashflow Yield

-101.41%

CNTX Fundamentals

CNTX Earnings

Earnings (TTM)

-24.0M

Earnings Growth (Yr)

-90.34%

Earnings Growth (Qtr)

-15.24%

Breaking Down CNTX Revenue

Last 7 days

-5.1%

Last 30 days

8.3%

Last 90 days

6.6%

Trailing 12 Months

116.7%

How does CNTX drawdown profile look like?

CNTX Financial Health

Current Ratio

3.83

CNTX Investor Care

Diluted EPS (TTM)

-1.5

Tracking the Latest Insider Buys and Sells of Context Therapeutics Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 21, 2023
lehr martin a.
bought
4,900
0.8415
5,823
chief executive officer
Feb 13, 2023
lehr martin a.
bought
4,900
0.8742
5,606
chief executive officer
Feb 06, 2023
lehr martin a.
bought
4,900
0.9723
5,040
chief executive officer
Jan 30, 2023
lehr martin a.
bought
4,900
0.6974
7,027
chief executive officer
Jan 23, 2023
lehr martin a.
bought
4,900
0.7166
6,839
chief executive officer
Jan 17, 2023
lehr martin a.
bought
4,995
0.7364
6,783
chief executive officer
Dec 16, 2022
lehr martin a.
bought
14,796
0.7398
20,000
chief executive officer
Dec 16, 2022
minai-azary jennifer lynn
bought
18,500
0.74
25,000
chief financial officer
Dec 09, 2022
levit alex c.
bought
5,094
0.8491
6,000
chief legal officer, corp. sec
Aug 19, 2022
lehr martin a.
bought
24,064
1.8511
13,000
chief executive officer

1–10 of 22

Which funds bought or sold CNTX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Mar 11, 2024
VANGUARD GROUP INC
added
0.42
-222,677
673,494
-%
Feb 14, 2024
STATE STREET CORP
unchanged
-
-12,505
37,185
-%
Feb 14, 2024
BANK OF AMERICA CORP /DE/
added
9.00
-28.00
123
-%
Feb 14, 2024
Mill Creek Capital Advisors, LLC
unchanged
-
-39,760
118,233
-%
Feb 14, 2024
Ally Bridge Group (NY) LLC
unchanged
-
-275,861
820,325
0.49%
Feb 14, 2024
Retirement Group, LLC
unchanged
-
-59.00
175
-%
Feb 14, 2024
Opaleye Management Inc.
new
-
1,101,750
1,101,750
0.29%
Feb 14, 2024
UBS OCONNOR LLC
added
0.33
-111,264
335,243
0.02%
Feb 14, 2024
BRIDGEWAY CAPITAL MANAGEMENT, LLC
unchanged
-
-40,208
119,564
-%

1–10 of 29

Are Funds Buying or Selling CNTX?

Are funds buying CNTX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CNTX
No. of Funds

Unveiling Context Therapeutics Inc.'s Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
affinity asset advisors, llc
2.06%
328,817
SC 13G/A
Feb 07, 2024
lehr martin a.
8.8%
1,452,466
SC 13G/A
Jan 05, 2024
opaleye management inc.
5.14%
820,000
SC 13G
Feb 14, 2023
context therapeutics inc.
7.3%
1,186,102
SC 13G
Jan 10, 2023
sabby management, llc
4.99%
796,706
SC 13G/A
Jan 09, 2023
hirschman orin
0%
0
SC 13G/A
Oct 27, 2022
hirschman orin
8.1%
1,285,771
SC 13G
May 09, 2022
affinity asset advisors, llc
5.53%
883,654
SC 13G
Feb 02, 2022
hudson bay capital management lp
8.36%
1e+06
SC 13G

Recent SEC filings of Context Therapeutics Inc.

View All Filings
Date Filed Form Type Document
Apr 01, 2024
8-K
Current Report
Mar 22, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading
Mar 22, 2024
4
Insider Trading
Mar 21, 2024
S-8
Employee Benefits Plan
Mar 21, 2024
8-K
Current Report
Mar 21, 2024
10-K
Annual Report
Mar 06, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 07, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Context Therapeutics Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
40.2B
6.8B
2.01% -33.59%
-8.52
5.86
-64.45% -156.37%
22.4B
152.6K
-0.77% 465779.94%
-2.4K
146.8K
- -9.98%
19.7B
1.8B
4.15% -26.04%
-44.64
10.75
76.23% 61.08%
16.5B
2.4B
1.55% -12.37%
98.23
6.81
15.42% 18.43%
12.4B
3.7B
-8.31% -27.12%
20.68
3.34
8.87% 75.42%
MID-CAP
6.5B
396.6M
-12.77% -31.76%
-12.26
16.35
425.83% 18.94%
5.0B
-
-2.52% 80.97%
-7.6
60.35
54.84% -34.79%
3.4B
270.6M
-2.48% 20.65%
-14.28
12.62
440.80% -27.84%
3.2B
240.7M
-23.17% -1.80%
-10.73
13.23
-1.03% -92.09%
2.9B
726.4M
-24.02% -2.94%
-47.88
4.04
40.45% 71.62%
SMALL-CAP
1.8B
398.2M
-4.62% -10.82%
25.58
4.59
85.90% -14.05%
620.0M
983.7M
-18.72% -47.64%
-1.14
0.63
-50.36% 17.16%
419.8M
881.7K
-10.95% 416.26%
-9.41
466.16
-77.61% -5.33%
264.3M
4.9M
11.10% 22.40%
-1.96
54.31
-54.97% 51.72%
7.9M
2.1M
91.53% 83.74%
-0.29
2.14
-13.45% 66.37%

Context Therapeutics Inc. News

Latest updates
InvestorsObserver01 Apr 202403:19 pm

Context Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42019Q4
Assets-30.1%16.0023.0028.0032.0038.0042.0045.0047.0051.002.002.001.001.000.00
  Current Assets-30.1%16.0023.0028.0032.0038.0042.0044.0047.0051.000.00--0.000.00
    Cash Equivalents-33.3%14.0022.0025.0030.0035.0039.0043.0046.0050.000.001.002.000.000.00
  Net PPE-14.2%0.000.000.000.000.000.000.000.00------
Liabilities-9.0%4.005.004.003.003.004.003.002.003.004.006.008.0010.0024.00
  Current Liabilities-9.0%4.005.004.003.003.004.003.002.003.004.00--10.0024.00
    LT Debt, Current-------------6.0021.00
Shareholder's Equity-35.4%12.0018.0024.0029.0035.0038.0042.0045.0048.00-----
  Retained Earnings-11.0%-68.05-61.30-55.40-50.40-44.09-40.50-36.68-32.69-29.25-26.16---18.80-25.44
  Additional Paid-In Capital0.3%80.0080.0079.0079.0079.0079.0078.0078.0078.003.00--2.001.00
Shares Outstanding0%16.0016.0016.0016.0016.0016.0016.0016.0016.00-0.000.000.000.00
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32019Q4
Cashflow From Operations-108.8%-7,227-3,460-4,631-5,728-3,929-2,994-2,805-3,820-4,961-43.63-2,078-1,715---
  Share Based Compensation0.4%25625528328324427724121520416211926.00---
Cashflow From Investing-------500-1.84-35.00---250----
Cashflow From Financing---------10254,228-8161,9483,035---

CNTX Income Statement

2023-12-31
Consolidated Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Operating expenses:  
Acquired in-process research and development$ 0$ 500,000
Research and development17,782,7317,091,163
General and administrative7,289,8857,790,040
Loss from operations(25,072,616)(15,381,203)
Interest income1,163,975547,268
Other expense(55,570)(2,004)
Net loss$ (23,964,211)$ (14,835,939)
Net income (loss) per share - basic (in dollars per share)$ (1.50)$ (0.93)
Net income (loss) per share - diluted (in dollars per share)$ (1.50)$ (0.93)
Weighted average common shares outstanding - basic (in shares)15,966,05315,966,053
Weighted average common shares outstanding - diluted (in shares)15,966,05315,966,053

CNTX Balance Sheet

2023-12-31
Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 14,449,827$ 35,497,445
Prepaid expenses and other current assets1,597,3842,356,213
Total current assets16,047,21137,853,658
Operating lease right-of-use asset051,967
Property and equipment, net15,52427,568
Other assets032,750
Total assets16,062,73537,965,943
Current liabilities:  
Accounts payable2,383,016936,330
Accrued expenses and other current liabilities1,808,6992,216,169
Operating lease liability - current055,078
Total current liabilities4,191,7153,207,577
Total liabilities4,191,7153,207,577
Commitments and contingencies
Stockholders' equity:  
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding00
Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 issued and outstanding at December 31, 2023 and December 31, 202215,96615,966
Additional paid-in capital79,909,64478,832,779
Accumulated deficit(68,054,590)(44,090,379)
Total stockholders' equity11,871,02034,758,366
Total liabilities and stockholders' equity$ 16,062,735$ 37,965,943
CNTX
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
 CEO
 WEBSITEcontexttherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES9

Context Therapeutics Inc. Frequently Asked Questions


What is the ticker symbol for Context Therapeutics Inc.? What does CNTX stand for in stocks?

CNTX is the stock ticker symbol of Context Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Context Therapeutics Inc. (CNTX)?

As of Mon Apr 08 2024, market cap of Context Therapeutics Inc. is 20.76 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CNTX stock?

You can check CNTX's fair value in chart for subscribers.

What is the fair value of CNTX stock?

You can check CNTX's fair value in chart for subscribers. The fair value of Context Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Context Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CNTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Context Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether CNTX is over valued or under valued. Whether Context Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Context Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNTX.